Vitamin D Receptor Inhibits NLRP3 Activation by Impeding Its BRCC3-Mediated Deubiquitination.
Level 5 - mechanism / opinion, no new human data
Preclinical in vitro and animal mechanistic research without human data
PubMed 31866999 · doi:10.3389/fimmu.2019.02783
What was done
The authors investigated the molecular role of the vitamin D receptor (VDR) in regulating NLRP3 inflammasome activation. They tested the physical binding of VDR to NLRP3 and BRCC3, assessed BRCC3-mediated deubiquitination and NLRP3 oligomerization, and evaluated caspase-1 activation and IL-1β release in VDR-deficient mice subjected to LPS-induced or alum-induced peritoneal inflammation.
What was found
No quantitative data or numerical values were reported in the abstract. Qualitatively, VDR physically bound NLRP3 and blocked its association with the deubiquitinase BRCC3, thereby preventing NLRP3 deubiquitination and oligomerization. In mice, absence of VDR increased caspase-1 activation and IL-1β release following LPS or alum challenge, whereas vitamin D via VDR signaling inhibited IL-1β secretion.
Why it matters
This work identifies a direct biochemical mechanism by which vitamin D receptor signaling suppresses NLRP3 inflammasome assembly. It provides mechanistic support for targeting VDR signaling in NLRP3-driven autoimmune and inflammatory disorders.
Limits
The study is entirely preclinical, relying on cell culture and mouse models of acute inflammation without human clinical data. The abstract omits sample sizes, exact effect sizes, and variance metrics.
Cited by
- supports Activation of the vitamin D receptor downregulates the NLRP3 inflammasome.